* Nymox reports successful new phase 3 long-term fexapotide
repeat injection bph trial results: lasting symptomatic
improvement up to 6 years after single repeated treatment
The post BRIEF-Nymox reports successful new phase 3 long-term Fexapotide repeat injection BPH trial results appeared first on NASDAQ.